Search

Your search keyword '"Eder, Sandra"' showing total 47 results
Start Over Author "Eder, Sandra" Publication Year Range Last 10 years
47 results on '"Eder, Sandra"'

4. R‐ketorolac ameliorates cancer‐associated cachexia and prolongs survival of tumour‐bearing mice

Author

Chrysostomou, Sophia E., primary, Eder, Sandra, additional, Pototschnig, Isabella, additional, Mayer, Anna‐Lena, additional, Derler, Martina, additional, Mussbacher, Marion, additional, Schauer, Silvia, additional, Zhang, Dongxu, additional, Yan, Dongmei, additional, Liu, Gennie, additional, Hoefler, Gerald, additional, Weichhart, Thomas, additional, Vesely, Paul W., additional, Zhang, Lingbing, additional, and Schweiger, Martina, additional

Published
2024
Full Text
View/download PDF

19. Advanced lipodystrophy reverses fatty liver in mice lacking adipocyte hormone-sensitive lipase

Author

Pajed, Laura, Taschler, Ulrike, Tilp, Anna, Hofer, Peter, Kotzbeck, Petra, Kolleritsch, Stephanie, Radner, Franz P. W., Pototschnig, Isabella, Wagner, Carina, Schratter, Margarita, Eder, Sandra, Huetter, Sabrina, Schreiber, Renate, Haemmerle, Guenter, Eichmann, Thomas O., Schweiger, Martina, Hoefler, Gerald, Kershaw, Erin E., Lass, Achim, and Schoiswohl, Gabriele

Published
2021
Full Text
View/download PDF

20. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, primary, Vladimer, Gregory I., primary, Bayer, Günther, primary, Bergmann, Michael, primary, Eder, Sandra, primary, Eichner, Ruth, primary, Erl, Martin, primary, Esterbauer, Harald, primary, Exner, Ruth, primary, Felsleitner-Hauer, Verena, primary, Forte, Maurizio, primary, Gaiger, Alexander, primary, Geissler, Klaus, primary, Greinix, Hildegard T., primary, Gstöttner, Wolfgang, primary, Hacker, Marcus, primary, Hartmann, Bernd Lorenz, primary, Hauswirth, Alexander W., primary, Heinemann, Tim, primary, Heintel, Daniel, primary, Hoda, Mir Alireza, primary, Hopfinger, Georg, primary, Jaeger, Ulrich, primary, Kazianka, Lukas, primary, Kenner, Lukas, primary, Kiesewetter, Barbara, primary, Krall, Nikolaus, primary, Krajnik, Gerhard, primary, Kubicek, Stefan, primary, Le, Trang, primary, Lubowitzki, Simone, primary, Mayerhoefer, Marius E., primary, Menschel, Elisabeth, primary, Merkel, Olaf, primary, Miura, Katsuhiro, primary, Müllauer, Leonhard, primary, Neumeister, Peter, primary, Noesslinger, Thomas, primary, Ocko, Katharina, primary, Öhler, Leopold, primary, Panny, Michael, primary, Pichler, Alexander, primary, Porpaczy, Edit, primary, Prager, Gerald W., primary, Raderer, Markus, primary, Ristl, Robin, primary, Ruckser, Reinhard, primary, Salamon, Julius, primary, Schiefer, Ana-Iris, primary, Schmolke, Ann-Sofie, primary, Schwarzinger, Ilse, primary, Selzer, Edgar, primary, Sillaber, Christian, primary, Skrabs, Cathrin, primary, Sperr, Wolfgang R., primary, Srndic, Ismet, primary, Thalhammer, Renate, primary, Valent, Peter, primary, van der Kouwe, Emiel, primary, Vanura, Katrina, primary, Vogt, Stefan, primary, Waldstein, Cora, primary, Wolf, Dominik, primary, Zielinski, Christoph C., primary, Zojer, Niklas, primary, Simonitsch-Klupp, Ingrid, primary, Superti-Furga, Giulio, primary, Snijder, Berend, primary, and Staber, Philipp B., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, primary, Vladimer, Gregory I., primary, Bayer, Günther, primary, Bergmann, Michael, primary, Eder, Sandra, primary, Eichner, Ruth, primary, Erl, Martin, primary, Esterbauer, Harald, primary, Exner, Ruth, primary, Felsleitner-Hauer, Verena, primary, Forte, Maurizio, primary, Gaiger, Alexander, primary, Geissler, Klaus, primary, Greinix, Hildegard T., primary, Gstöttner, Wolfgang, primary, Hacker, Marcus, primary, Hartmann, Bernd Lorenz, primary, Hauswirth, Alexander W., primary, Heinemann, Tim, primary, Heintel, Daniel, primary, Hoda, Mir Alireza, primary, Hopfinger, Georg, primary, Jaeger, Ulrich, primary, Kazianka, Lukas, primary, Kenner, Lukas, primary, Kiesewetter, Barbara, primary, Krall, Nikolaus, primary, Krajnik, Gerhard, primary, Kubicek, Stefan, primary, Le, Trang, primary, Lubowitzki, Simone, primary, Mayerhoefer, Marius E., primary, Menschel, Elisabeth, primary, Merkel, Olaf, primary, Miura, Katsuhiro, primary, Müllauer, Leonhard, primary, Neumeister, Peter, primary, Noesslinger, Thomas, primary, Ocko, Katharina, primary, Öhler, Leopold, primary, Panny, Michael, primary, Pichler, Alexander, primary, Porpaczy, Edit, primary, Prager, Gerald W., primary, Raderer, Markus, primary, Ristl, Robin, primary, Ruckser, Reinhard, primary, Salamon, Julius, primary, Schiefer, Ana-Iris, primary, Schmolke, Ann-Sofie, primary, Schwarzinger, Ilse, primary, Selzer, Edgar, primary, Sillaber, Christian, primary, Skrabs, Cathrin, primary, Sperr, Wolfgang R., primary, Srndic, Ismet, primary, Thalhammer, Renate, primary, Valent, Peter, primary, van der Kouwe, Emiel, primary, Vanura, Katrina, primary, Vogt, Stefan, primary, Waldstein, Cora, primary, Wolf, Dominik, primary, Zielinski, Christoph C., primary, Zojer, Niklas, primary, Simonitsch-Klupp, Ingrid, primary, Superti-Furga, Giulio, primary, Snijder, Berend, primary, and Staber, Philipp B., primary

Published
2023
Full Text
View/download PDF

22. Fasting-induced G0/G1 switch gene 2 and FGF21 expression in the liver are under regulation of adipose tissue derived fatty acids

Author

Jaeger, Doris, Schoiswohl, Gabriele, Hofer, Peter, Schreiber, Renate, Schweiger, Martina, Eichmann, Thomas O., Pollak, Nina M., Poecher, Nadja, Grabner, Gernot F., Zierler, Kathrin A., Eder, Sandra, Kolb, Dagmar, Radner, Franz P.W., Preiss-Landl, Karina, Lass, Achim, Zechner, Rudolf, Kershaw, Erin E., and Haemmerle, Guenter

Published
2015
Full Text
View/download PDF

23. Thiotepa‐based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched‐pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Eder, Sandra, Canaani, Jonathan, Beohou, Eric, Labopin, Myriam, Sanz, Jaime, Arcese, William, Or, Reuven, Finke, Juergen, Cortelezzi, Agostino, Beelen, Dietrich, Passweg, Jakob, Socié, Gerard, Gurman, Gunhan, Aljurf, Mahmoud, Stelljes, Matthias, Giebel, Sebastian, Mohty, Mohamad, and Nagler, Arnon

Published
2017
Full Text
View/download PDF

28. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, additional, Vladimer, Gregory I., additional, Bayer, Günther, additional, Bergmann, Michael, additional, Eder, Sandra, additional, Eichner, Ruth, additional, Erl, Martin, additional, Esterbauer, Harald, additional, Exner, Ruth, additional, Felsleitner-Hauer, Verena, additional, Forte, Maurizio, additional, Gaiger, Alexander, additional, Geissler, Klaus, additional, Greinix, Hildegard T., additional, Gstöttner, Wolfgang, additional, Hacker, Marcus, additional, Hartmann, Bernd Lorenz, additional, Hauswirth, Alexander W., additional, Heinemann, Tim, additional, Heintel, Daniel, additional, Hoda, Mir Alireza, additional, Hopfinger, Georg, additional, Jaeger, Ulrich, additional, Kazianka, Lukas, additional, Kenner, Lukas, additional, Kiesewetter, Barbara, additional, Krall, Nikolaus, additional, Krajnik, Gerhard, additional, Kubicek, Stefan, additional, Le, Trang, additional, Lubowitzki, Simone, additional, Mayerhoefer, Marius E., additional, Menschel, Elisabeth, additional, Merkel, Olaf, additional, Miura, Katsuhiro, additional, Müllauer, Leonhard, additional, Neumeister, Peter, additional, Noesslinger, Thomas, additional, Ocko, Katharina, additional, Öhler, Leopold, additional, Panny, Michael, additional, Pichler, Alexander, additional, Porpaczy, Edit, additional, Prager, Gerald W., additional, Raderer, Markus, additional, Ristl, Robin, additional, Ruckser, Reinhard, additional, Salamon, Julius, additional, Schiefer, Ana-Iris, additional, Schmolke, Ann-Sofie, additional, Schwarzinger, Ilse, additional, Selzer, Edgar, additional, Sillaber, Christian, additional, Skrabs, Cathrin, additional, Sperr, Wolfgang R., additional, Srndic, Ismet, additional, Thalhammer, Renate, additional, Valent, Peter, additional, van der Kouwe, Emiel, additional, Vanura, Katrina, additional, Vogt, Stefan, additional, Waldstein, Cora, additional, Wolf, Dominik, additional, Zielinski, Christoph C., additional, Zojer, Niklas, additional, Simonitsch-Klupp, Ingrid, additional, Superti-Furga, Giulio, additional, Snijder, Berend, additional, and Staber, Philipp B., additional

Published
2021
Full Text
View/download PDF

29. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Eder, Sandra, Labopin, Myriam, Arcese, William, Or, Reuven, Majolino, Ignazio, Bacigalupo, Andrea, de Rosa, Gennaro, Volin, Liisa, Beelen, Dietrich, Veelken, Hendrik, Schaap, Nicolaas P. M., Kuball, Jurgen, Cornelissen, Jan, Nagler, Arnon, and Mohty, Mohamad

Published
2016
Full Text
View/download PDF

30. Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Author

Kornauth, Christoph, primary, Pemovska, Tea, additional, Vladimer, Gregory Ian, additional, Bayer, Günther, additional, Bergmann, Michael, additional, Eder, Sandra, additional, Eichner, Ruth, additional, Esterbauer, Harald, additional, Exner, Ruth, additional, Felsleitner-Hauer, Verena, additional, Forte, Maurizio, additional, Gaiger, Alexander, additional, Greinix, Hildegard T., additional, Gstöttner, Wolfgang, additional, Hacker, Marcus, additional, Hauswirth, Alexander, additional, Heinemann, Tim, additional, Heintel, Daniel, additional, Hoda, Mir Ali Reza, additional, Jaeger, Ulrich, additional, Kazianka, Lukas, additional, Kenner, Lukas, additional, Kiesewetter, Barbara, additional, Krall, Nikolaus, additional, Le, Trang, additional, Lubowitzki, Simone, additional, Mayerhoefer, Marius E, additional, Menschel, Elisabeth, additional, Merkel, Olaf, additional, Miura, Katsuhiro, additional, Muellauer, Leonhard, additional, Neumeister, Peter, additional, Noesslinger, Thomas, additional, Ocko, Katharina, additional, Öhler, Leopold, additional, Panny, Michael, additional, Pichler, Alexander, additional, Porpaczy, Edit Anna, additional, Prager, Gerald, additional, Raderer, Markus, additional, Ristl, Robin, additional, Ruckser, Reinhard, additional, Salamon, Julius, additional, Schiefer, Ana-Iris, additional, Schmolke, Ann-Sofie, additional, Schwarzinger, Ilse, additional, Selzer, Edgar, additional, Skrabs, Cathrin, additional, Sperr, Wolfgang R., additional, Srndic, Ismet, additional, Thalhammer, Renate, additional, Valent, Peter, additional, van der Kouwe, Emiel, additional, Vanura, Katrina, additional, Vogt, Stefan, additional, Waldstein, Cora, additional, Wolf, Dominik, additional, Zielinski, Christoph, additional, Simonitsch-Klupp, Ingrid, additional, Superti-Furga, Giulio, additional, Snijder, Berend, additional, and Staber, Philipp B., additional

Published
2020
Full Text
View/download PDF

31. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience

Author

Sestili, Simona, primary, Eder, Sandra, additional, Belhocine, Ramdane, additional, Dulery, Remy, additional, Battipaglia, Giorgia, additional, Brissot, Eolia, additional, Mediavilla, Clemence, additional, Banet, Anne, additional, van de Wyngaert, Zoe, additional, Paviglianiti, Annalisa, additional, Ledraa, Tounes, additional, Bonin, Agnes, additional, Mohty, Mohamad, additional, and Malard, Florent, additional

Published
2020
Full Text
View/download PDF

32. Intestine‐Specific Overexpression of Carboxylesterase 2c Protects Mice From Diet‐Induced Liver Steatosis and Obesity

Author

Maresch, Lisa Katharina, primary, Benedikt, Pia, additional, Feiler, Ursula, additional, Eder, Sandra, additional, Zierler, Kathrin A., additional, Taschler, Ulrike, additional, Kolleritsch, Stephanie, additional, Eichmann, Thomas O., additional, Schoiswohl, Gabriele, additional, Leopold, Christina, additional, Wieser, Beatrix I., additional, Lackner, Caroline, additional, Rülicke, Thomas, additional, van Klinken, Jan, additional, Kratky, Dagmar, additional, Moustafa, Tarek, additional, Hoefler, Gerald, additional, and Haemmerle, Guenter, additional

Published
2018
Full Text
View/download PDF

35. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia

Author

Battipaglia, Giorgia, Ruggeri, Annalisa, Massoud, Radwan, El Cheikh, Jean, Jestin, Matthieu, Antar, Ahmad, Ahmed, Syed Osman, Rasheed, Walid, Shaheen, Marwan, Belhocine, Ramdane, Brissot, Eolia, Dulery, Remy, Eder, Sandra, Giannotti, Federica, Isnard, Françoise, Lapusan, Simona, Rubio, Marie-Thérèse, Vekhoff, Anne, Aljurf, Mahmoud, Legrand, Ollivier, Mohty, Mohamad, Bazarbachi, Ali, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Università degli studi di Napoli Federico II, American University of Beirut Faculty of Medicine and Medical Center (AUB), King Faisal Specialist Hospital and Research Centre, Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL), Battipaglia, G., Ruggeri, A., Massoud, R., El Cheikh, J., Jestin, M., Antar, A., Ahmed, S. O., Rasheed, W., Shaheen, M., Belhocine, R., Brissot, E., Dulery, R., Eder, S., Giannotti, F., Isnard, F., Lapusan, S., Rubio, M. -T., Vekhoff, A., Aljurf, M., Legrand, O., Mohty, M., and Bazarbachi, A.

Subjects
Adult, Male, Niacinamide, Phenylurea Compound, Fms-like tyrosine kinase 3 (FLT3), Adolescent, [SDV]Life Sciences [q-bio], Graft vs Host Disease, Antineoplastic Agents, Disease-Free Survival, maintenance, Maintenance Chemotherapy, Antineoplastic Agent, Young Adult, acute myeloid leukemia (AML), allogeneic stem cell transplantation, Retrospective Studie, Humans, Transplantation, Homologous, Transplantation, Homologou, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, Phenylurea Compounds, Hematopoietic Stem Cell Transplantation, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, Sorafenib, Feasibility Studie, Leukemia, Myeloid, Acute, Treatment Outcome, fms-Like Tyrosine Kinase 3, Chemotherapy, Adjuvant, Feasibility Studies, Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Human
Abstract

BACKGROUND: Sorafenib has shown encouraging results in patients with Fms-like tyrosine kinase 3 (FLT3)-positive acute myeloid leukemia. Its role after allogeneic stem cell transplantation (HSCT) has been reported in a few cases with encouraging results. METHODS: The authors describe the use of sorafenib as a maintenance agent after HSCT in 27 patients with FLT3-positive acute myeloid leukemia. RESULTS: The median age of the patients was 46 years (range, 15-57 years). Sorafenib was introduced at a median of 70 days (range, 29-337 days) after HSCT. The median treatment duration was 8.4 months (range, 0.2-46 months). Eleven patients experienced treatment toxicities, mainly of grade 1 to 2 (graded according to the National Cancer Institute Common Toxicity Criteria [version 4.0]). Dose reduction or withdrawal was required in 4 patients and 4 patients, respectively. The persistence of toxicity prompted treatment withdrawal in 1 patient. Clinical improvement followed dose modifications. Thirteen patients experienced chronic graft-versus-host disease (limited in 9 patients and extensive in 4 patients), resulting in dose reduction in 5 patients followed by withdrawal in 1 of these individuals. At a median follow-up of 18 months (range, 4-48 months), 25 patients were alive (all of whom were in complete molecular remission) and 18 were still receiving treatment, with 1-year overall survival and progression-free survival rates of 92% ± 6% and 92% ± 5%, respectively. CONCLUSIONS: Sorafenib treatment after HSCT appears to be feasible and highly effective with dose individualization according to patient tolerability. Further analysis is needed to evaluate the immunomodulating role of sorafenib after HSCT. The data from the current support prospective controlled trials of sorafenib after HSCT. Cancer 2017;123:2867–74. © 2017 American Cancer Society.

Published
2017

37. Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Author

Battipaglia, Giorgia, primary, Ruggeri, Annalisa, additional, Jestin, Matthieu, additional, Massoud, Radwan, additional, El Cheikh, Jean, additional, Antar, Ahmad, additional, Ahmed, Syed Osman, additional, Rasheed, Walid, additional, Belhocine, Ramdane, additional, Brissot, Eolia, additional, Dulery, Remy, additional, Eder, Sandra, additional, Giannotti, Federica, additional, Isnard, Francoise, additional, Lapusan, Simona, additional, Rubio, Marie-Thérèse, additional, Vekhoff, Anne, additional, Aljurf, Mahmoud, additional, Legrand, Ollivier, additional, Mohty, Mohamad, additional, and Bazarbachi, Ali, additional

Published
2016
Full Text
View/download PDF

38. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Eder, Sandra, primary, Beohou, Eric, additional, Labopin, Myriam, additional, Sanz, Jaime, additional, Finke, Jürgen, additional, Arcese, William, additional, Or, Reuven, additional, Bonifazi, Francesca, additional, Aljurf, Mahmoud, additional, Socié, Gerard, additional, Passweg, Jakob, additional, Giebel, Sebastian, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2016
Full Text
View/download PDF

39. Intestine‐Specific Overexpression of Carboxylesterase 2c Protects Mice From Diet‐Induced Liver Steatosis and Obesity.

Author

Maresch, Lisa Katharina, Benedikt, Pia, Feiler, Ursula, Eder, Sandra, Zierler, Kathrin A., Taschler, Ulrike, Kolleritsch, Stephanie, Eichmann, Thomas O., Schoiswohl, Gabriele, Leopold, Christina, Wieser, Beatrix I., Lackner, Caroline, Rülicke, Thomas, van Klinken, Jan, Kratky, Dagmar, Moustafa, Tarek, Hoefler, Gerald, and Haemmerle, Guenter

Subjects
CARBOXYLESTERASES, FATTY degeneration, FATTY liver, TRIGLYCERIDES, LIPID metabolism, PREVENTION of obesity, DIET in disease, LABORATORY mice
Abstract

Murine hepatic carboxylesterase 2c (Ces2c) and the presumed human ortholog carboxylesterase 2 (CES2) have been implicated in the development of nonalcoholic fatty liver disease (NAFLD) in mice and obese humans. These studies demonstrated that Ces2c hydrolyzes triglycerides (TGs) in hepatocytes. Interestingly, Ces2c/CES2 is most abundantly expressed in the intestine, indicating a role of Ces2c/CES2 in intestinal TG metabolism. Here we show that Ces2c is an important enzyme in intestinal lipid metabolism in mice. Intestine‐specific Ces2c overexpression (Ces2cint) provoked increased fatty acid oxidation (FAO) in the small intestine accompanied by enhanced chylomicron clearance from the circulation. As a consequence, high‐fat diet–fed Ces2cint mice were resistant to excessive diet‐induced weight gain and adipose tissue expansion. Notably, intestinal Ces2c overexpression increased hepatic insulin sensitivity and protected mice from NAFLD development. Although lipid absorption was not affected in Ces2cint mice, fecal energy content was significantly increased. Mechanistically, we demonstrate that Ces2c is a potent neutral lipase, which efficiently hydrolyzes TGs and diglycerides (DGs) in the small intestine, thereby generating fatty acids (FAs) for FAO and monoglycerides (MGs) and DGs for potential re‐esterification. Consequently, the increased availability of MGs and DGs for re‐esterification and primordial apolipoprotein B48 particle lipidation may increase chylomicron size, ultimately mediating more efficient chylomicron clearance from the circulation. Conclusion: This study suggests a critical role for Ces2c in intestinal lipid metabolism and highlights the importance of intestinal lipolysis to protect mice from the development of hepatic insulin resistance, NAFLD, and excessive diet‐induced weight gain during metabolic stress. In this study, we investigated the role of carboxylesterase 2c (Ces2c) in the intestine. Low levels of Ces2c in the liver was recently linked to the development of nonalcoholic fatty liver disease. Here we show that increasing Ces2c protein abundance in the intestine protected mice from excessive diet‐induced weight gain and most importantly NAFLD development by altering intestinal lipid catabolism, thereby affecting whole body energy metabolism. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Eder, Sandra, primary, Beohou, Eric, additional, Labopin, Myriam, additional, Sanz, Jaime, additional, Finke, Jürgen, additional, Arcese, William, additional, Or, Reuven, additional, Bonifazi, Francesca, additional, Cortelezzi, Agostino, additional, Majolino, Ignazio, additional, Bacigalupo, Andrea, additional, Spyridonidis, Alexandros, additional, Alessandrino, Emilio Paolo, additional, Giebel, Sebastian, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2015
Full Text
View/download PDF

41. Extracorporeal Photopheresis (ECP) for Acute Graft-Versus Host Disease (GvHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Author

Eder, Sandra, primary, Rubio, Marie-Thérèse, additional, Belhocine, Ramdane, additional, Labopin, Myriam, additional, Brissot, Eolia, additional, Mamez, Anne-Claire, additional, Giannotti, Federica, additional, Battipaglia, Giorgia, additional, Ruggeri, Annalisa, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2015
Full Text
View/download PDF

42. Report: EBMT 2015

Author

Eder, Sandra, additional, Collignon, Aude, additional, Paillassa, Jerome, additional, Sutra Del Galy, Aurélien, additional, Battipaglia, Giorgia, additional, Le Bourgeois, Amandine, additional, and Malard, Florent, additional

Published
2015
Full Text
View/download PDF

43. Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Eder, Sandra, primary, Labopin, Myriam, additional, Finke, Jurgen, additional, Bunjes, Donald W., additional, Olivieri, Attilio, additional, Santarone, Stella, additional, Rambaldi, Alessandro, additional, Kanz, Lothar, additional, Messina, Giuseppe, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2014
Full Text
View/download PDF

44. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis

Author

Brahma, Manoja K., primary, Adam, Rene C., additional, Pollak, Nina M., additional, Jaeger, Doris, additional, Zierler, Kathrin A., additional, Pöcher, Nadja, additional, Schreiber, Renate, additional, Romauch, Matthias, additional, Moustafa, Tarek, additional, Eder, Sandra, additional, Ruelicke, Thomas, additional, Preiss-Landl, Karina, additional, Lass, Achim, additional, Zechner, Rudolf, additional, and Haemmerle, Guenter, additional

Published
2014
Full Text
View/download PDF

46. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Author

Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, and Staber PB

Subjects
Adult, Aged, Aged, 80 and over, Austria, Cohort Studies, Female, Hematologic Neoplasms mortality, Humans, Male, Middle Aged, Molecular Targeted Therapy, Precision Medicine, Progression-Free Survival, Young Adult, Hematologic Neoplasms drug therapy
Abstract

Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. A promising method may be drug profiling of patient biopsy specimens with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers. Fifty-six patients (39%) were treated according to scFPM results. At a median follow-up of 23.9 months, 30 patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease. We conclude that therapy matching by scFPM is clinically feasible and effective in advanced aggressive hematologic cancers. SIGNIFICANCE: This is the first precision medicine trial using a functional assay to instruct n-of-one therapies in oncology. It illustrates that for patients lacking standard therapies, high-content assay-based scFPM can have a significant value in clinical therapy guidance based on functional dependencies of each patient's cancer. See related commentary by Letai, p. 290 . This article is highlighted in the In This Issue feature, p. 275 ., (©2021 The Authors; Published by the American Association for Cancer Research.)

Published
2022
Full Text
View/download PDF

47. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Author

Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, and Bazarbachi A

Subjects
Adolescent, Adult, Chemotherapy, Adjuvant, Disease-Free Survival, Feasibility Studies, Female, Graft vs Host Disease, Humans, Leukemia, Myeloid, Acute genetics, Maintenance Chemotherapy, Male, Middle Aged, Niacinamide therapeutic use, Retrospective Studies, Sorafenib, Transplantation, Homologous, Treatment Outcome, Young Adult, fms-Like Tyrosine Kinase 3 genetics, Antineoplastic Agents therapeutic use, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute drug therapy, Niacinamide analogs & derivatives, Phenylurea Compounds therapeutic use
Abstract

Background: Sorafenib has shown encouraging results in patients with Fms-like tyrosine kinase 3 (FLT3)-positive acute myeloid leukemia. Its role after allogeneic stem cell transplantation (HSCT) has been reported in a few cases with encouraging results., Methods: The authors describe the use of sorafenib as a maintenance agent after HSCT in 27 patients with FLT3-positive acute myeloid leukemia., Results: The median age of the patients was 46 years (range, 15-57 years). Sorafenib was introduced at a median of 70 days (range, 29-337 days) after HSCT. The median treatment duration was 8.4 months (range, 0.2-46 months). Eleven patients experienced treatment toxicities, mainly of grade 1 to 2 (graded according to the National Cancer Institute Common Toxicity Criteria [version 4.0]). Dose reduction or withdrawal was required in 4 patients and 4 patients, respectively. The persistence of toxicity prompted treatment withdrawal in 1 patient. Clinical improvement followed dose modifications. Thirteen patients experienced chronic graft-versus-host disease (limited in 9 patients and extensive in 4 patients), resulting in dose reduction in 5 patients followed by withdrawal in 1 of these individuals. At a median follow-up of 18 months (range, 4-48 months), 25 patients were alive (all of whom were in complete molecular remission) and 18 were still receiving treatment, with 1-year overall survival and progression-free survival rates of 92% ± 6% and 92% ± 5%, respectively., Conclusions: Sorafenib treatment after HSCT appears to be feasible and highly effective with dose individualization according to patient tolerability. Further analysis is needed to evaluate the immunomodulating role of sorafenib after HSCT. The data from the current support prospective controlled trials of sorafenib after HSCT. Cancer 2017;123:2867-74. © 2017 American Cancer Society., (© 2017 American Cancer Society.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results